These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33990570)

  • 1. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer.
    Shi W; Zhang G; Ma Z; Li L; Liu M; Qin L; Yu Z; Zhao L; Liu Y; Zhang X; Qin J; Ye H; Jiang X; Zhou H; Sun H; Jiao Z
    Nat Commun; 2021 May; 12(1):2812. PubMed ID: 33990570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT/mTOR and ERK/mTOR axis.
    Qiao J; Feng M; Zhou W; Tan Y; Yang S; Liu Q; Wang Q; Feng W; Pan Y; Cui L
    Gastric Cancer; 2024 Jul; 27(4):785-801. PubMed ID: 38782859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.
    Saatci Ö; Borgoni S; Akbulut Ö; Durmuş S; Raza U; Eyüpoğlu E; Alkan C; Akyol A; Kütük Ö; Wiemann S; Şahin Ö
    Oncogene; 2018 Apr; 37(17):2251-2269. PubMed ID: 29391599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
    Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
    BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition.
    Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
    Mol Cancer Ther; 2017 Jun; 16(6):1145-1154. PubMed ID: 28223426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-301a-3p induced by endoplasmic reticulum stress mediates the occurrence and transmission of trastuzumab resistance in HER2-positive gastric cancer.
    Guo J; Zhong X; Tan Q; Yang S; Liao J; Zhuge J; Hong Z; Deng Q; Zuo Q
    Cell Death Dis; 2021 Jul; 12(7):696. PubMed ID: 34257270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGF-induced nuclear translocation of SHCBP1 promotes bladder cancer progression through inhibiting RACGAP1-mediated RAC1 inactivation.
    Yin H; Zhang C; Wei Z; He W; Xu N; Xu Y; Li T; Ren K; Kuang Y; Zhu X; Yuan F; Yu H; Gou X
    Cell Death Dis; 2022 Jan; 13(1):39. PubMed ID: 35013128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
    Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
    Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer.
    Ishida M; Kagawa S; Shimoyama K; Takehara K; Noma K; Tanabe S; Shirakawa Y; Tazawa H; Kobayashi H; Fujiwara T
    Mol Cancer Ther; 2016 Mar; 15(3):402-11. PubMed ID: 26832799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.
    Piro G; Carbone C; Cataldo I; Di Nicolantonio F; Giacopuzzi S; Aprile G; Simionato F; Boschi F; Zanotto M; Mina MM; Santoro R; Merz V; Sbarbati A; de Manzoni G; Scarpa A; Tortora G; Melisi D
    Clin Cancer Res; 2016 Dec; 22(24):6164-6175. PubMed ID: 27267856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
    Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Wnt3a/β-catenin/TCF7L2 signaling axis reduces the sensitivity of HER2-positive epithelial ovarian cancer to trastuzumab.
    Shen G; Gao Q; Liu F; Zhang Y; Dai M; Zhao T; Cheng M; Xu T; Jin P; Yin W; Huang D; Weng H; Chen W; Ren H; Mu X; Wu X; Hu S
    Biochem Biophys Res Commun; 2020 Jun; 526(3):685-691. PubMed ID: 32248976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition.
    Shi J; Li F; Yao X; Mou T; Xu Z; Han Z; Chen S; Li W; Yu J; Qi X; Liu H; Li G
    Oncogene; 2018 May; 37(22):3022-3038. PubMed ID: 29535422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in
    Gambardella V; Gimeno-Valiente F; Tarazona N; Martinez-Ciarpaglini C; Roda D; Fleitas T; Tolosa P; Cejalvo JM; Huerta M; Roselló S; Castillo J; Cervantes A
    Clin Cancer Res; 2019 Mar; 25(5):1639-1649. PubMed ID: 30504425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
    Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.
    Nam HJ; Ching KA; Kan J; Kim HP; Han SW; Im SA; Kim TY; Christensen JG; Oh DY; Bang YJ
    Mol Cancer Ther; 2012 Feb; 11(2):439-51. PubMed ID: 22135232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SHCBP1 promotes tumor cell proliferation, migration, and invasion, and is associated with poor prostate cancer prognosis.
    Xu N; Wu YP; Yin HB; Chen SH; Li XD; Xue XY; Gou X
    J Cancer Res Clin Oncol; 2020 Aug; 146(8):1953-1969. PubMed ID: 32447485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy.
    Darini C; Ghaddar N; Chabot C; Assaker G; Sabri S; Wang S; Krishnamoorthy J; Buchanan M; Aguilar-Mahecha A; Abdulkarim B; Deschenes J; Torres J; Ursini-Siegel J; Basik M; Koromilas AE
    Nat Commun; 2019 May; 10(1):2139. PubMed ID: 31086176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylation of Plk1 at S137 and T210 is inhibited in response to DNA damage.
    Tsvetkov L; Stern DF
    Cell Cycle; 2005 Jan; 4(1):166-71. PubMed ID: 15611664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
    Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
    Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.